Novartis (NVS) Discontinues Development of 'Lu-NeoB,' a GRPR-Targeted Radioligand Therapy, Following Clinical Trial Failure
Background and Reasons for the Discontinuation of Lu-NeoB Development
Novartis has decided to discontinue all clinical development of 'Lu-NeoB ([177Lu]Lu-NeoB),' a radioligand therapy (RLT) candidate targeting the gastrin-releasing peptide receptor (GRPR). This decision was made due to the underwhelming efficacy data observed in a Phase 1 clinical trial for breast cancer and a Phase 2 clinical trial for various solid tumors. While no significant safety concerns were identified, the early clinical data did not demonstrate sufficient therapeutic efficacy to justify further development.
Strategic Portfolio Adjustment to Maintain Leadership in Modality
For Novartis, a global leader in the radiopharmaceutical market, this discontinuation represents a proactive risk management decision rather than a failure of the entire platform. By halting the Phase 2 trial, which was scheduled to continue as a long-term study until 2031 in combination with chemotherapy, Novartis aims to prevent resource waste and allocate resources to more promising pipeline assets. The issue likely stems from the design of the candidate or its receptor-binding affinity, and it is not expected to significantly impact Novartis' overall RLT platform.
Diversification Strategy for Next-Generation RLT and ADC Portfolios
Vas Narasimhan, CEO of Novartis, reiterated the company's unwavering commitment to the RLT modality. Novartis has a robust pipeline of next-generation RLT candidates to follow the success of Pluvicto and Lutathera, which have achieved significant market success in the treatment of prostate cancer and neuroendocrine tumors. In addition to Ac-PSMA-617, a late-stage pipeline asset based on actinium-225 (Ac-225) targeting PSMA, clinical trials are actively underway for Phase 1/2 assets targeting DLL3, HER2, and FAP. Furthermore, with the acquisition of Myricx Bio for $1.1 billion earlier this month, Novartis is expanding its oncology portfolio by incorporating an antibody-drug conjugate (ADC) platform.
Competitive Landscape and Future Prospects of the GRPR-Targeted Market
The global radiopharmaceutical market is currently experiencing rapid growth, with a size of approximately $7.5 billion to $9.2 billion USD. The GRPR receptor is a highly attractive biomarker, as it is overexpressed in breast cancer and prostate cancer. Although Novartis has discontinued Lu-NeoB, competitors such as Eli Lilly, which is developing a GRPR antagonist candidate 'LY4257496' in Phase 1 clinical trials, and Orano Med, which is developing a lead-212 (Pb-212)-based alpha therapy '212Pb-GRPR,' remain active in the field. Therefore, the RLT industry is expected to focus on technological advancements to overcome the challenges of GRPR-targeted therapy by introducing more stable ligand designs and innovative radionuclide combinations.
Novartis' discontinuation of the Phase 2 trial for Lu-NeoB highlights the limitations of early-stage GRPR-targeted RLTs, but it does not diminish the long-term growth potential of the RLT modality in the global radiopharmaceutical market, which is valued at $7.5 billion to $9.2 billion USD. In the short term, the failure of this asset will likely improve Novartis' R&D cost efficiency, and in the medium to long term, it is expected to complement the ADC pipeline of Myricx Bio, which was acquired for $1.1 billion this month, to strengthen its oncology portfolio. Researchers and industry observers should pay attention to the evolving competitive landscape with Eli Lilly's GRPR antagonist 'LY4257496' and Orano Med's alpha particle therapy '212Pb-GRPR,' both of which are in Phase 1 clinical trials for the same indications. Ultimately, investors should assess the sustainability of the revenue growth of Pluvicto, an approved blockbuster therapy, and the speed of transition to late-stage clinical trials for next-generation RLTs, such as Ac-PSMA-617, as key indicators of Novartis' competitiveness in the RLT sector.